Description: Combined monthly injectable.

Product Details

Duration: Monthly


Dose: 25 mg MPA, 5 mg estradiol cypionate

Active Pharmaceutical Ingredient (API):

Status Details

Developer: , , ,

Status Details:
  • CycloFem is registered and in use in Mexico, Indonesia, Thailand, Hong Kong, and a few countries in Latin America. Concept Foundation has the commercial rights. CONRAD conducted PK studies on CycloFem to support the US FDA approval process.
  • The same formulation was previously approved by the US FDA as Lunelle (in 2000), marketed by Pfizer, but was removed from the market because of production problems.
  • Cyclofem was added to the WHO Model List of Essential Medicines in 2007.

Additional Information


Vertical Tabs